ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................*JBDM Ver 0.1.63 (23 May 2017) - 2999001/02954068CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120181031W173deBibliographieenBibliographyfrBibliographieEP14706699.7201402042015090720160902enenen201361761105 P20130205US2018103120184420151216201551201809052018362017080820181031201844C12Q 1/68 20180101AFI20140825BHEP deWIRKSTOFFAUSWAHL FÜR EINE THERAPIE GEGEN NICHT-KLEINZELLIGEN LUNGENKREBSenDRUG SELECTION FOR NON-SMALL CELL LUNG CANCER THERAPYfrSÉLECTION D'UN MÉDICAMENT POUR UNE THÉRAPIE ANTICANCÉREUSE DU CANCER DU POUMON NON À PETITES CELLULESWO-A1-2011/008990WO-A1-2012/088337WO-A2-2012/119113N HOE ET AL: "Selection of targeted agent(s) based on matching differential protein expression and mutational profile in NSCLC patients.", JOURNAL OF CLINICAL ONCOLOGY, vol. 29, no. 15_suppl, 20 May 2011 (2011-05-20), page e21085, XP055020717,HUA C. GONG ET AL: "Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer", INTERNATIONAL JOURNAL OF PROTEOMICS, vol. 2011, 1 January 2011 (2011-01-01), pages 1-13, XP055030274, ISSN: 2090-2166, DOI: 10.1155/2011/215496SINGH, Sharat8171 Top of the Morning WayRancho Santa Fe California 92127USKIM, Phillip28 ExeterIrvine California 92612USLOCKTON, Steven9410 Carroll Park DriveSan Diego California 92121USPierian Holdings, Inc.101671256N408158EP405 Duke Drive, Suite 240Franklin, TN 37067USJ A Kemp10166966614 South Square Gray's InnLondon WC1R 5JJGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRIB201405879020140204enWO201412258220140814201433